Skip to main content
Smart Investors Daily
Actinium Pharmaceuticals, Inc. logo

AMEX · ATNM

Actinium Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.64

Down-$0.15 (-9.15%)

Updated Nov 17, 2026, 1:10 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.55M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$0.74 – $1.72
Volume
180.62K
Avg. volume
205.89K

Price performance · ATNM

ATNM price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

ATNM closed at $1.64 after 20 trading sessions, up 24.24% for the selected period.

Last close
$1.64
Period change
+24.24%
Period low
$1.30
Period high
$1.64
Daily close
View OHLC price history
ATNM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$1.60$1.64$1.55$1.64180.62K
Nov 12, 2026$1.61$1.67$1.53$1.59348.12K
Nov 11, 2026$1.52$1.65$1.49$1.59115.53K
Nov 10, 2026$1.55$1.61$1.50$1.57176.42K
Nov 9, 2026$1.44$1.6201$1.43$1.54468.37K
Nov 6, 2026$1.28$1.43$1.28$1.4389.25K
Nov 5, 2026$1.38$1.39$1.30$1.30213.04K
Nov 4, 2026$1.42$1.45$1.3601$1.41104.26K
Nov 3, 2026$1.40$1.46$1.40$1.4075.84K
Nov 2, 2026$1.48$1.53$1.41$1.43104.58K
Oct 30, 2026$1.51$1.535$1.45$1.48157.72K
Oct 29, 2026$1.38$1.56$1.38$1.53181.67K
Oct 28, 2026$1.40$1.42$1.35$1.3856.56K
Oct 27, 2026$1.40$1.55$1.40$1.42106.95K
Oct 26, 2026$1.50$1.53$1.36$1.40205.86K
Oct 23, 2026$1.60$1.63$1.469$1.52242.01K
Oct 22, 2026$1.33$1.66$1.33$1.60828.82K
Oct 21, 2026$1.38$1.4087$1.33$1.38358.23K
Oct 20, 2026$1.36$1.50$1.3501$1.40901.05K
Oct 19, 2026$1.14$1.40$1.13$1.32658.4K

Latest ATNM news

The latest Smart Investors Daily articles mentioning ATNM.

ATNM research

Overview

Company profile and research snapshot.

Company profile

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.07
Implied upside
—
Analysts
11
ATNM recent ratings
DateFirmRatingTarget
Mar 31, 2026Stephens & Co.Overweight—
Jun 24, 2025HC Wainwright & Co.Buy—
May 12, 2025HC Wainwright & Co.Buy—
Apr 28, 2025HC Wainwright & Co.Buy—
Apr 1, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar on Tuesday, December 1, 2026, at 8:00 a.m. ET to discuss the evolving treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) and the potential of ATNM-400, its investigational, first-in-class, HER3-targeted Actinium-225 antibody radioconjugate.

Yahoo · Nov 11, 2026

Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that the RADIANZ ("Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89") clinical trial is enrolling patients. RADIANZ is an imaging study of ⁸⁹Zr-Barecetamab-DFO using PET to guide the pan-tumor development of ²²⁵Ac-Barecetamab-DOTA (ATNM-400) in solid tumors outside of prostat

Yahoo · Nov 9, 2026

ATNM: Introducing ATNM-400's HER3 Target

By John Vandermosten, CFA NYSE: ATNM READ THE FULL ATNM RESEARCH REPORT Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has contributed to a whirlwind of activity related to its ATNM-400, conditioning and hematological assets through a series of posters and presentations at several important medical conferences. It recently revealed ATNM-400’s target and generated a number of posters and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.